LINDIS BIOTECH
LINDIS Biotech was founded to develop ektomun®, an innovative immunotherapeutic for the treatment of small cell lung cancer, melanoma and other neuroectodermal cancers that currently lack sufficient treatment options.
LINDIS BIOTECH
Industry:
Biotechnology
Address:
Martinsried, Bayern, Germany
Country:
Germany
Website Url:
http://www.lindisbiotech.com
Status:
Active
Contact:
+498970076624
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Apple Mobile Web Clips Icon WordPress Mobile Non Scaleable Content Sitelinks Search Box Euro Organization Schema Yoast WordPress SEO Plugin Yoast SEO Premium
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
TripleMed
TripleMed aims to develop innovative and cost-effective solutions for the treatment of aortic aneurysms.
Vaxira
Vaxira is a therapeutic vaccine for the treatment of non-small cell lung cancer
Official Site Inspections
http://www.lindisbiotech.com
- Host name: 217-160-0-46.elastic-ssl.ui-r.com
- IP address: 217.160.0.46
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "LINDIS Biotech"
Lindis Biotech · Empowering the Immune System Against Cancer
Lindis Biotech is a clinical stage bio-pharmaceutical company that is committed to the development of Triomab® antibodies – a new class of T-cell engaging bispecific antibodies, …See details»
Scientific & Pharmaceutical Experience - Lindis Biotech, …
Lindis Biotech is a clinical stage bio-pharmaceutical company, committed to develop innovative T- cell engaging trifunctional bispecific antibodies, Triomab® to turn malignant cancers into manageable and possibly curable diseases.See details»
About Lindis - Lindis Biotech GmbH - Innovations- und …
Lindis Biotech GmbH, a clinical stage bio-pharmaceutical company with a proprietary multi-specific antibody platform and an advanced development pipeline with three clinical product …See details»
LINDIS Biotech - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +498970076624 LINDIS Biotech was founded to develop ektomun®, an innovative immunotherapeutic for the treatment of …See details»
Scientific Publications & News · Lindis Biotech, Munich
Oct 21, 2024 · LINDIS Biotech is a clinical stage bio-pharmaceutical company that is committed to the development of Triomab® antibodies – a new class of T-cell engaging bispecific …See details»
Lindis Biotech - Overview, News & Similar companies - ZoomInfo
View Lindis Biotech (www.lindisbiotech.com) location in Bavaria, Germany , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
Lindis Biotech (Lindis Biotech GmbH) - Startbase
Brauchst du Hilfe? Entwicklung von Triomab®-Antikörpern – einer neuen Klasse von T-Zell-aktivierenden bispezifischen Antikörpern, die das Immunsystem befähigen, bösartige …See details»
LINDIS Biotech GmbH | Insights
Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Press Release LINDIS Biotech receives Positive CHMP Opinion for …
Oct 21, 2024 · experience demonstrates the profound impact catumaxomab can have on patients facing this critical condition. We are therefore thrilled that the CHMP has recommended …See details»
LINDIS Biotech publishes data from Phase I dose escalation trial of ...
LINDIS Biotech GmbH, a biopharmaceutical company with a proprietary multi-specific antibody platform and an advanced development pipeline with three clinical product candidates in …See details»
LINDIS Biotech Signs Licensing Agreement with Pharmanovia for …
Munich, Germany, November 19, 2024 – LINDIS Biotech GmbH, a clinical stage biopharmaceutical company with a proprietary multi-specific antibody platform and an …See details»
Press Release LINDIS Biotech Announces Online Publication of …
Lti-specific antibody platform and an advanced development pipeline with three clinical product candidates in immuno-oncology, was founded in 2010 by Dr. Horst Lindhofer, inventor of the …See details»
LINDIS Biotech Signs Licensing Agreement with Pharmanovia for …
Nov 19, 2024 · The agreement gives Pharmanovia the exclusive rights to bring to market, catumaxomab, a first-in-class, trifunctional bi-specific monoclonal antibody, indicated for the …See details»
LINDIS Biotech Announces Online Publication of Abstract on ...
Jun 1, 2022 · LINDIS Biotech is the only company that owns a technology which combines extremely effective tumor cell destruction with a patient-specific vaccination based on …See details»
LINDIS Biotech Presented Encouraging Data from Non-Muscle …
Nov 14, 2022 · LINDIS Biotech is the only company that owns a technology which combines extremely effective tumor cell destruction with a patient-specific vaccination based on …See details»
LINDIS Biotech präsentiert Daten der Phase-I-Dosis …
Der vom Martinsrieder Unternehmen LINDIS Biotech auf der Jahrestagung der American Society of Clinical Oncology (ASCO) veröffentlichte Abstract zeigt klinische Daten aus der Phase-I …See details»
Press Release - Lindis Biotech
Dec 21, 2021 · n immuno-oncology, was founded in 2010 by Dr. Horst Lindhofer, inventor of the Triomab® platform. LINDIS Biotech is the only company that owns a technology which …See details»
Lindis Biotech entwickelt Immuntherapie gegen Blasenkrebs
Apr 13, 2021 · Die Biotech-Firma im Innovations- und Gründerzentrum Biotechnologie IZB bei München meldet erfolgreichen Start ihrer klinischen Phase-I-Dosiseskalationsstudie mit dem …See details»
LINDIS Biotech Announces Online Publication of Abstract on ...
Jan 6, 2022 · LINDIS Biotech GmbH, a biopharmaceutical company with a proprietary multi-specific antibody platform and an advanced development pipeline with three clinical product …See details»
Press Release - Lindis Biotech
Nov 14, 2022 · d an advanced development pipeline with three clinical product candidates in immuno-oncology, was founded in 2010 by Dr. Horst Lindhofer, inventor of the Triomab® …See details»